Priority Reviews Propel FDA To Six-Year Low In Average NME Approval Time
This article was originally published in Pharmaceutical Approvals Monthly
FDA's decrease in average new molecular entity approval time in 2005 was driven by an unusual preponderance of priority review drugs
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class